Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInvested CapitalMarket CapitalizationNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Sales

Crinetics Pharmaceuticals (CRNX) EBT Margin: 2017-2025

Historic EBT Margin for Crinetics Pharmaceuticals (CRNX) over the last 6 years, with Sep 2025 value amounting to -90,972.73%.

  • Crinetics Pharmaceuticals' EBT Margin was N/A to -90,972.73% in Q3 2025 from the same period last year, while for Sep 2025 it was -21,856.05%, marking a year-over-year change of. This contributed to the annual value of -28,625.51% for FY2024, which is 2341315.00% down from last year.
  • As of Q3 2025, Crinetics Pharmaceuticals' EBT Margin stood at -90,972.73%, which was down 710.96% from -11,217.94% recorded in Q2 2025.
  • Over the past 5 years, Crinetics Pharmaceuticals' EBT Margin peaked at -1,074.23% during Q1 2022, and registered a low of -90,972.73% during Q3 2025.
  • Its 3-year average for EBT Margin is -22,626.50%, with a median of -13,760.42% in 2025.
  • Over the last 5 years, Crinetics Pharmaceuticals' EBT Margin had its largest YoY gain of 733,895bps in 2025, and its largest YoY loss of 1,640,581bps in 2025.
  • Crinetics Pharmaceuticals' EBT Margin (Quarterly) stood at -6,438.93% in 2022, then tumbled by 714,263bps to -16,302.89% in 2023, then plummeted by 1,340,628bps to -18,556.89% in 2024, then skyrocketed by 733,895bps to -90,972.73% in 2025.
  • Its EBT Margin stands at -90,972.73% for Q3 2025, versus -11,217.94% for Q2 2025 and -26,750.97% for Q1 2025.